| 1 | newer | 2,353 |
| 2 | classical | 1,951 |
| 3 | classic | 1,648 |
| 4 | competing | 910 |
| 5 | so-called | 769 |
| 6 | steroidal | 249 |
| 7 | triphasic | 144 |
| 8 | nontraditional | 132 |
| 9 | non-traditional | 128 |
| 10 | non-hormonal | 90 |
| 11 | omics | 73 |
| 12 | potassium-sparing | 53 |
| 13 | non-targeted | 50 |
| 14 | symplicity | 47 |
| 15 | prototypic | 44 |
| 16 | enzyme-inducing | 34 |
| 17 | lng-20 | 34 |
| 18 | nonstandard | 34 |
| 19 | commonly-used | 33 |
| 20 | non-biologic | 32 |
| 21 | nonulcerative | 29 |
| 22 | nonconventional | 26 |
| 23 | non-aspirin | 23 |
| 24 | nontherapeutic | 22 |
| 25 | fibrin-specific | 19 |
| 26 | morse | 18 |
| 27 | 'first | 17 |
| 28 | large-size | 17 |
| 29 | nonbiologic | 16 |
| 30 | omic | 16 |
| 31 | looped | 14 |
| 32 | very-high | 13 |
| 33 | non-naproxen | 12 |
| 34 | half-strength | 11 |
| 35 | methylating | 11 |
| 36 | one-handed | 11 |
| 37 | atrial-selective | 10 |
| 38 | belief-based | 10 |
| 39 | fourteen-day | 10 |
| 40 | levonorgestrel-containing | 10 |
| 41 | valsartan-based | 10 |
| 42 | nonbranded | 9 |
| 43 | nonvasodilating | 9 |
| 44 | single-rod | 9 |
| 45 | 2,3-diaryl-indole | 8 |
| 46 | off-patent | 8 |
| 47 | older-generation | 8 |
| 48 | sensititre | 8 |
| 49 | water-related | 8 |
| 50 | lab-on-a-chip | 7 |
| 51 | non-adrenergic | 7 |
| 52 | nonthoracotomy | 7 |
| 53 | rifampicin/minocycline-impregnated | 7 |
| 54 | tcm-derived | 7 |
| 55 | anti-her | 6 |
| 56 | assist-as-needed | 6 |
| 57 | cardio-selective | 6 |
| 58 | cdse/zns | 6 |
| 59 | non-enzyme-inducing | 6 |
| 60 | single-cycle | 6 |
| 61 | stealth | 6 |
| 62 | sur2a | 6 |
| 63 | animacy-violated | 5 |
| 64 | benzodiazepine-like | 5 |
| 65 | currently-available | 5 |
| 66 | dehp-free | 5 |
| 67 | microbial-associated | 5 |
| 68 | necessity-concerns | 5 |
| 69 | non-fluorinated | 5 |
| 70 | non-thoracotomy | 5 |
| 71 | polycentric | 5 |
| 72 | qi-invigorating | 5 |
| 73 | reproductive-related | 5 |
| 74 | single-sourced | 5 |
| 75 | tamper-resistant | 5 |
| 76 | vaidya | 5 |
| 77 | 2-series | 4 |
| 78 | 3,294 | 4 |
| 79 | 4-ring | 4 |
| 80 | adenovirus-based | 4 |
| 81 | alpha5 | 4 |
| 82 | cardio-enriched | 4 |
| 83 | current-generation | 4 |
| 84 | double-hit | 4 |
| 85 | hbsag-specific | 4 |
| 86 | hcrnav34 | 4 |
| 87 | heat-released | 4 |
| 88 | lactose-based | 4 |
| 89 | lowest-dose | 4 |
| 90 | non-diuretic | 4 |
| 91 | non-estrogenic | 4 |
| 92 | non-paroxetine | 4 |
| 93 | non-thiazide | 4 |
| 94 | nupro | 4 |
| 95 | pl-supplemented | 4 |
| 96 | self-propagating | 4 |
| 97 | single-indicator | 4 |
| 98 | structurally-related | 4 |
| 99 | tarsocrural | 4 |
| 100 | wingless-type | 4 |
| 101 | workplace-related | 4 |
| 102 | 1.2.4 | 3 |
| 103 | 1.2.5 | 3 |
| 104 | 4.0-cm | 3 |
| 105 | 46-item | 3 |
| 106 | amyloid-based | 3 |
| 107 | anti-cox-2 | 3 |
| 108 | anti-illicit-drug | 3 |
| 109 | citrate-coated | 3 |
| 110 | core/shell/shell | 3 |
| 111 | dsg+ee | 3 |
| 112 | emotion-sensitive | 3 |
| 113 | f-cuins2 | 3 |
| 114 | gnp-bound | 3 |
| 115 | head-worn | 3 |
| 116 | high-and | 3 |
| 117 | incretin-related | 3 |
| 118 | mid-risk | 3 |
| 119 | most-prescribed | 3 |
| 120 | nanostructure-based | 3 |
| 121 | non-cox-2-selective | 3 |
| 122 | non-fda-approved | 3 |
| 123 | nonhereditary | 3 |
| 124 | nonnaproxen | 3 |
| 125 | parent-identified | 3 |
| 126 | pbca-allicin | 3 |
| 127 | pre-close | 3 |
| 128 | quasireversible | 3 |
| 129 | replication-born | 3 |
| 130 | rs10993994 | 3 |
| 131 | triple-chamber | 3 |
| 132 | wrong-way | 3 |
| 133 | zno-1 | 3 |
| 134 | 3192 | 2 |
| 135 | adaptive-use | 2 |
| 136 | all-swcnt | 2 |
| 137 | ch'an | 2 |
| 138 | chemokine-containing | 2 |
| 139 | clinopodioides | 2 |
| 140 | contrast-free | 2 |
| 141 | corinthian | 2 |
| 142 | cox-2‑transfected | 2 |
| 143 | desynchronizing | 2 |
| 144 | fe₃o₄-plla-peg-plla | 2 |
| 145 | first‑line | 2 |
| 146 | gastrotoxic | 2 |
| 147 | glua2-containing | 2 |
| 148 | glycine-containing | 2 |
| 149 | help-me | 2 |
| 150 | high-chlorinated | 2 |
| 151 | homegrown | 2 |
| 152 | hrpii-based | 2 |
| 153 | hypoxia-preconditioned | 2 |
| 154 | lag-3+ | 2 |
| 155 | liqudation | 2 |
| 156 | lng+ee | 2 |
| 157 | lowdose | 2 |
| 158 | melt-extruded | 2 |
| 159 | non-aurophilic | 2 |
| 160 | non-cannabis | 2 |
| 161 | non-dissection | 2 |
| 162 | non-glp-1 | 2 |
| 163 | non-rifampicin-impregnated | 2 |
| 164 | nonlipophilic | 2 |
| 165 | nonregulated | 2 |
| 166 | prestorage-filtered | 2 |
| 167 | receptor-directed | 2 |
| 168 | scratch-like | 2 |
| 169 | sequus | 2 |
| 170 | shorter-lasting | 2 |
| 171 | single-action | 2 |
| 172 | size-1 | 2 |
| 173 | soil-associated | 2 |
| 174 | src-3+/ar-/syp+ | 2 |
| 175 | surface-adsorbed | 2 |
| 176 | tlr3-activated | 2 |
| 177 | value-ordered | 2 |
| 178 | wide-brimmed | 2 |
| 179 | xanthophyll-cycle | 2 |
| 180 | xiebai | 2 |
| 181 | zhenju | 2 |
| 182 | zno-2 | 2 |
| 183 | α-class | 2 |
| 184 | -statin | 1 |
| 185 | 0-84-year | 1 |
| 186 | 1-ethyl-3-methylimidazolium-based | 1 |
| 187 | 1.2.3.2 | 1 |
| 188 | 19,942.9-21,974.4 | 1 |
| 189 | 19370 | 1 |
| 190 | 21,914.5-21,974.4 | 1 |
| 191 | 22-12-2005 | 1 |
| 192 | 23,764 | 1 |
| 193 | 39049 | 1 |
| 194 | 3hdd-containing | 1 |
| 195 | 43,082.5-43,142.4 | 1 |
| 196 | 5,438 | 1 |
| 197 | 5-nm | 1 |
| 198 | 71,112 | 1 |
| 199 | aceis/ | 1 |
| 200 | alexandrium-causing | 1 |
| 201 | alimenta | 1 |
| 202 | antiglycaemic | 1 |
| 203 | antihypertenive | 1 |
| 204 | antiresorbing | 1 |
| 205 | arb-pretreated | 1 |
| 206 | arb/ccb/ | 1 |
| 207 | b-zr-b | 1 |
| 208 | behavior-oriented | 1 |
| 209 | biochar-bound | 1 |
| 210 | bzd-related | 1 |
| 211 | cadmium-containing | 1 |
| 212 | cd3+cd4+cd25+cd127low | 1 |
| 213 | cd45-/cd144+/kdr+ | 1 |
| 214 | cd83+ | 1 |
| 215 | cdse-zns | 1 |
| 216 | cellular-connected | 1 |
| 217 | circumplanetary | 1 |
| 218 | cisplatin-modified | 1 |
| 219 | citrate-capped | 1 |
| 220 | clopidogrel/no | 1 |
| 221 | cndac-induced | 1 |
| 222 | coated-type | 1 |
| 223 | community-diagnosed | 1 |
| 224 | cone-driven | 1 |
| 225 | cox-2‑modified | 1 |
| 226 | cox2-preferential | 1 |
| 227 | crt-no | 1 |
| 228 | cyp2d6-blocking | 1 |
| 229 | daily/occasional | 1 |
| 230 | dasatinib-pretreated | 1 |
| 231 | dearabinosylated | 1 |
| 232 | denv-3-driven | 1 |
| 233 | desault | 1 |
| 234 | di-ortho | 1 |
| 235 | dsg/gsd | 1 |
| 236 | eim-generated | 1 |
| 237 | emotions-the | 1 |
| 238 | enzyme-resistant | 1 |
| 239 | et-conjugated | 1 |
| 240 | etoricoxib-treated | 1 |
| 241 | first-available | 1 |
| 242 | ftnl-treated | 1 |
| 243 | full-time-equivalent | 1 |
| 244 | gamma-gliadin-specific | 1 |
| 245 | gbz188-2007 | 1 |
| 246 | glucose-and | 1 |
| 247 | good-moderate | 1 |
| 248 | hads-defined | 1 |
| 249 | heparin-impregnated | 1 |
| 250 | heterochromatin-associated | 1 |
| 251 | hrp2-based | 1 |
| 252 | hsp60-binding | 1 |
| 253 | hucb-derived | 1 |
| 254 | hyperdiverse | 1 |
| 255 | hypo-oncotic | 1 |
| 256 | hypusinated | 1 |
| 257 | iatrikos | 1 |
| 258 | ido1-deficiency | 1 |
| 259 | ifnb-induced | 1 |
| 260 | igeκ-sensitized | 1 |
| 261 | il-2-boosted | 1 |
| 262 | imidazolium-derived | 1 |
| 263 | ingredient-specific | 1 |
| 264 | injury-group-detected | 1 |
| 265 | intracellular-localised | 1 |
| 266 | intrinsic/acquired | 1 |
| 267 | irs-ii | 1 |
| 268 | isotretinoin-associated | 1 |
| 269 | ixygenated | 1 |
| 270 | laba/reduced | 1 |
| 271 | lag-3-activated | 1 |
| 272 | levodopa-the | 1 |
| 273 | life-when | 1 |
| 274 | lmw-specific | 1 |
| 275 | low-symptom | 1 |
| 276 | low-to-negligible | 1 |
| 277 | low-volume/low-intensity | 1 |
| 278 | lower-glycemic-index | 1 |
| 279 | maculo-canal | 1 |
| 280 | mdr-family | 1 |
| 281 | meso-erythritol-intercalated | 1 |
| 282 | microtubule-interfering | 1 |
| 283 | mir-103/7 | 1 |
| 284 | more-chlorinated | 1 |
| 285 | muassel | 1 |
| 286 | myofibril-bound | 1 |
| 287 | ncs-c-induced | 1 |
| 288 | ngr-targeted | 1 |
| 289 | nitrotirosine | 1 |
| 290 | nitroxide-labeled | 1 |
| 291 | no-tunnel | 1 |
| 292 | non-3'-sl | 1 |
| 293 | non-cox-selective | 1 |
| 294 | non-drospirenone-containing | 1 |
| 295 | non-fluoxetine | 1 |
| 296 | non-hydroxamate | 1 |
| 297 | non-lactose-based | 1 |
| 298 | non-orthologous | 1 |
| 299 | non-ppargamma-activating | 1 |
| 300 | non-self. | 1 |
| 301 | non-sympatholytic | 1 |
| 302 | non-third-generation | 1 |
| 303 | nonclozapine | 1 |
| 304 | nonsalicylate | 1 |
| 305 | nt-3-stimulated | 1 |
| 306 | nucleobase-modified | 1 |
| 307 | odontológicos | 1 |
| 308 | onsolis | 1 |
| 309 | osteocalcin+ | 1 |
| 310 | oth- | 1 |
| 311 | otj-trained | 1 |
| 312 | pandb-al₂o₃ | 1 |
| 313 | passaged-3 | 1 |
| 314 | pei-β-cyd-treated | 1 |
| 315 | pfhrp2-detecting | 1 |
| 316 | pgsi-type | 1 |
| 317 | pharmacist-recorded | 1 |
| 318 | phytoplankton-origin | 1 |
| 319 | pi3kγ-regulated | 1 |
| 320 | polypotent | 1 |
| 321 | power-limiting | 1 |
| 322 | ppar-gamma-activating | 1 |
| 323 | progastro | 1 |
| 324 | prozessmodell | 1 |
| 325 | radio-responsive | 1 |
| 326 | ronkoleykin | 1 |
| 327 | rrna-derived | 1 |
| 328 | rsmz | 1 |
| 329 | screening-instruments | 1 |
| 330 | self-life | 1 |
| 331 | sensory/nociceptor | 1 |
| 332 | sheepish | 1 |
| 333 | sigtuna | 1 |
| 334 | simulated-aged | 1 |
| 335 | sirt1-related | 1 |
| 336 | size-fractioned | 1 |
| 337 | soil-bound | 1 |
| 338 | strip-test | 1 |
| 339 | superimposes | 1 |
| 340 | surface-modifying | 1 |
| 341 | surface-protected | 1 |
| 342 | switched-to | 1 |
| 343 | t-helper-2-type | 1 |
| 344 | tcm. | 1 |
| 345 | tcr-specific | 1 |
| 346 | three-miktoarm | 1 |
| 347 | thrombocyte-rich | 1 |
| 348 | thymus-implanted | 1 |
| 349 | top-prescribed | 1 |
| 350 | transporter-based | 1 |
| 351 | transsylvian | 1 |
| 352 | tyrosine-reduced | 1 |
| 353 | vaginally-acquired | 1 |
| 354 | vapor-a | 1 |
| 355 | wax-intercalated | 1 |
| 356 | well-being-includes | 1 |
| 357 | well-populated | 1 |
| 358 | α4β2*-type | 1 |
| 359 | ∼100,000 | 1 |
| 1 | 'first | 17 |
| 2 | -statin | 1 |
| 3 | 0-84-year | 1 |
| 4 | 1-ethyl-3-methylimidazolium-based | 1 |
| 5 | 1.2.3.2 | 1 |
| 6 | 1.2.4 | 3 |
| 7 | 1.2.5 | 3 |
| 8 | 19,942.9-21,974.4 | 1 |
| 9 | 19370 | 1 |
| 10 | 2,3-diaryl-indole | 8 |
| 11 | 2-series | 4 |
| 12 | 21,914.5-21,974.4 | 1 |
| 13 | 22-12-2005 | 1 |
| 14 | 23,764 | 1 |
| 15 | 3,294 | 4 |
| 16 | 3192 | 2 |
| 17 | 39049 | 1 |
| 18 | 3hdd-containing | 1 |
| 19 | 4-ring | 4 |
| 20 | 4.0-cm | 3 |
| 21 | 43,082.5-43,142.4 | 1 |
| 22 | 46-item | 3 |
| 23 | 5,438 | 1 |
| 24 | 5-nm | 1 |
| 25 | 71,112 | 1 |
| 26 | aceis/ | 1 |
| 27 | adaptive-use | 2 |
| 28 | adenovirus-based | 4 |
| 29 | alexandrium-causing | 1 |
| 30 | alimenta | 1 |
| 31 | all-swcnt | 2 |
| 32 | alpha5 | 4 |
| 33 | amyloid-based | 3 |
| 34 | animacy-violated | 5 |
| 35 | anti-cox-2 | 3 |
| 36 | anti-her | 6 |
| 37 | anti-illicit-drug | 3 |
| 38 | antiglycaemic | 1 |
| 39 | antihypertenive | 1 |
| 40 | antiresorbing | 1 |
| 41 | arb-pretreated | 1 |
| 42 | arb/ccb/ | 1 |
| 43 | assist-as-needed | 6 |
| 44 | atrial-selective | 10 |
| 45 | b-zr-b | 1 |
| 46 | behavior-oriented | 1 |
| 47 | belief-based | 10 |
| 48 | benzodiazepine-like | 5 |
| 49 | biochar-bound | 1 |
| 50 | bzd-related | 1 |
| 51 | cadmium-containing | 1 |
| 52 | cardio-enriched | 4 |
| 53 | cardio-selective | 6 |
| 54 | cd3+cd4+cd25+cd127low | 1 |
| 55 | cd45-/cd144+/kdr+ | 1 |
| 56 | cd83+ | 1 |
| 57 | cdse-zns | 1 |
| 58 | cdse/zns | 6 |
| 59 | cellular-connected | 1 |
| 60 | ch'an | 2 |
| 61 | chemokine-containing | 2 |
| 62 | circumplanetary | 1 |
| 63 | cisplatin-modified | 1 |
| 64 | citrate-capped | 1 |
| 65 | citrate-coated | 3 |
| 66 | classic | 1,648 |
| 67 | classical | 1,951 |
| 68 | clinopodioides | 2 |
| 69 | clopidogrel/no | 1 |
| 70 | cndac-induced | 1 |
| 71 | coated-type | 1 |
| 72 | commonly-used | 33 |
| 73 | community-diagnosed | 1 |
| 74 | competing | 910 |
| 75 | cone-driven | 1 |
| 76 | contrast-free | 2 |
| 77 | core/shell/shell | 3 |
| 78 | corinthian | 2 |
| 79 | cox-2‑modified | 1 |
| 80 | cox-2‑transfected | 2 |
| 81 | cox2-preferential | 1 |
| 82 | crt-no | 1 |
| 83 | current-generation | 4 |
| 84 | currently-available | 5 |
| 85 | cyp2d6-blocking | 1 |
| 86 | daily/occasional | 1 |
| 87 | dasatinib-pretreated | 1 |
| 88 | dearabinosylated | 1 |
| 89 | dehp-free | 5 |
| 90 | denv-3-driven | 1 |
| 91 | desault | 1 |
| 92 | desynchronizing | 2 |
| 93 | di-ortho | 1 |
| 94 | double-hit | 4 |
| 95 | dsg+ee | 3 |
| 96 | dsg/gsd | 1 |
| 97 | eim-generated | 1 |
| 98 | emotion-sensitive | 3 |
| 99 | emotions-the | 1 |
| 100 | enzyme-inducing | 34 |
| 101 | enzyme-resistant | 1 |
| 102 | et-conjugated | 1 |
| 103 | etoricoxib-treated | 1 |
| 104 | f-cuins2 | 3 |
| 105 | fe₃o₄-plla-peg-plla | 2 |
| 106 | fibrin-specific | 19 |
| 107 | first-available | 1 |
| 108 | first‑line | 2 |
| 109 | fourteen-day | 10 |
| 110 | ftnl-treated | 1 |
| 111 | full-time-equivalent | 1 |
| 112 | gamma-gliadin-specific | 1 |
| 113 | gastrotoxic | 2 |
| 114 | gbz188-2007 | 1 |
| 115 | glua2-containing | 2 |
| 116 | glucose-and | 1 |
| 117 | glycine-containing | 2 |
| 118 | gnp-bound | 3 |
| 119 | good-moderate | 1 |
| 120 | hads-defined | 1 |
| 121 | half-strength | 11 |
| 122 | hbsag-specific | 4 |
| 123 | hcrnav34 | 4 |
| 124 | head-worn | 3 |
| 125 | heat-released | 4 |
| 126 | help-me | 2 |
| 127 | heparin-impregnated | 1 |
| 128 | heterochromatin-associated | 1 |
| 129 | high-and | 3 |
| 130 | high-chlorinated | 2 |
| 131 | homegrown | 2 |
| 132 | hrp2-based | 1 |
| 133 | hrpii-based | 2 |
| 134 | hsp60-binding | 1 |
| 135 | hucb-derived | 1 |
| 136 | hyperdiverse | 1 |
| 137 | hypo-oncotic | 1 |
| 138 | hypoxia-preconditioned | 2 |
| 139 | hypusinated | 1 |
| 140 | iatrikos | 1 |
| 141 | ido1-deficiency | 1 |
| 142 | ifnb-induced | 1 |
| 143 | igeκ-sensitized | 1 |
| 144 | il-2-boosted | 1 |
| 145 | imidazolium-derived | 1 |
| 146 | incretin-related | 3 |
| 147 | ingredient-specific | 1 |
| 148 | injury-group-detected | 1 |
| 149 | intracellular-localised | 1 |
| 150 | intrinsic/acquired | 1 |
| 151 | irs-ii | 1 |
| 152 | isotretinoin-associated | 1 |
| 153 | ixygenated | 1 |
| 154 | lab-on-a-chip | 7 |
| 155 | laba/reduced | 1 |
| 156 | lactose-based | 4 |
| 157 | lag-3+ | 2 |
| 158 | lag-3-activated | 1 |
| 159 | large-size | 17 |
| 160 | levodopa-the | 1 |
| 161 | levonorgestrel-containing | 10 |
| 162 | life-when | 1 |
| 163 | liqudation | 2 |
| 164 | lmw-specific | 1 |
| 165 | lng+ee | 2 |
| 166 | lng-20 | 34 |
| 167 | looped | 14 |
| 168 | low-symptom | 1 |
| 169 | low-to-negligible | 1 |
| 170 | low-volume/low-intensity | 1 |
| 171 | lowdose | 2 |
| 172 | lower-glycemic-index | 1 |
| 173 | lowest-dose | 4 |
| 174 | maculo-canal | 1 |
| 175 | mdr-family | 1 |
| 176 | melt-extruded | 2 |
| 177 | meso-erythritol-intercalated | 1 |
| 178 | methylating | 11 |
| 179 | microbial-associated | 5 |
| 180 | microtubule-interfering | 1 |
| 181 | mid-risk | 3 |
| 182 | mir-103/7 | 1 |
| 183 | more-chlorinated | 1 |
| 184 | morse | 18 |
| 185 | most-prescribed | 3 |
| 186 | muassel | 1 |
| 187 | myofibril-bound | 1 |
| 188 | nanostructure-based | 3 |
| 189 | ncs-c-induced | 1 |
| 190 | necessity-concerns | 5 |
| 191 | newer | 2,353 |
| 192 | ngr-targeted | 1 |
| 193 | nitrotirosine | 1 |
| 194 | nitroxide-labeled | 1 |
| 195 | no-tunnel | 1 |
| 196 | non-3'-sl | 1 |
| 197 | non-adrenergic | 7 |
| 198 | non-aspirin | 23 |
| 199 | non-aurophilic | 2 |
| 200 | non-biologic | 32 |
| 201 | non-cannabis | 2 |
| 202 | non-cox-2-selective | 3 |
| 203 | non-cox-selective | 1 |
| 204 | non-dissection | 2 |
| 205 | non-diuretic | 4 |
| 206 | non-drospirenone-containing | 1 |
| 207 | non-enzyme-inducing | 6 |
| 208 | non-estrogenic | 4 |
| 209 | non-fda-approved | 3 |
| 210 | non-fluorinated | 5 |
| 211 | non-fluoxetine | 1 |
| 212 | non-glp-1 | 2 |
| 213 | non-hormonal | 90 |
| 214 | non-hydroxamate | 1 |
| 215 | non-lactose-based | 1 |
| 216 | non-naproxen | 12 |
| 217 | non-orthologous | 1 |
| 218 | non-paroxetine | 4 |
| 219 | non-ppargamma-activating | 1 |
| 220 | non-rifampicin-impregnated | 2 |
| 221 | non-self. | 1 |
| 222 | non-sympatholytic | 1 |
| 223 | non-targeted | 50 |
| 224 | non-thiazide | 4 |
| 225 | non-third-generation | 1 |
| 226 | non-thoracotomy | 5 |
| 227 | non-traditional | 128 |
| 228 | nonbiologic | 16 |
| 229 | nonbranded | 9 |
| 230 | nonclozapine | 1 |
| 231 | nonconventional | 26 |
| 232 | nonhereditary | 3 |
| 233 | nonlipophilic | 2 |
| 234 | nonnaproxen | 3 |
| 235 | nonregulated | 2 |
| 236 | nonsalicylate | 1 |
| 237 | nonstandard | 34 |
| 238 | nontherapeutic | 22 |
| 239 | nonthoracotomy | 7 |
| 240 | nontraditional | 132 |
| 241 | nonulcerative | 29 |
| 242 | nonvasodilating | 9 |
| 243 | nt-3-stimulated | 1 |
| 244 | nucleobase-modified | 1 |
| 245 | nupro | 4 |
| 246 | odontológicos | 1 |
| 247 | off-patent | 8 |
| 248 | older-generation | 8 |
| 249 | omic | 16 |
| 250 | omics | 73 |
| 251 | one-handed | 11 |
| 252 | onsolis | 1 |
| 253 | osteocalcin+ | 1 |
| 254 | oth- | 1 |
| 255 | otj-trained | 1 |
| 256 | pandb-al₂o₃ | 1 |
| 257 | parent-identified | 3 |
| 258 | passaged-3 | 1 |
| 259 | pbca-allicin | 3 |
| 260 | pei-β-cyd-treated | 1 |
| 261 | pfhrp2-detecting | 1 |
| 262 | pgsi-type | 1 |
| 263 | pharmacist-recorded | 1 |
| 264 | phytoplankton-origin | 1 |
| 265 | pi3kγ-regulated | 1 |
| 266 | pl-supplemented | 4 |
| 267 | polycentric | 5 |
| 268 | polypotent | 1 |
| 269 | potassium-sparing | 53 |
| 270 | power-limiting | 1 |
| 271 | ppar-gamma-activating | 1 |
| 272 | pre-close | 3 |
| 273 | prestorage-filtered | 2 |
| 274 | progastro | 1 |
| 275 | prototypic | 44 |
| 276 | prozessmodell | 1 |
| 277 | qi-invigorating | 5 |
| 278 | quasireversible | 3 |
| 279 | radio-responsive | 1 |
| 280 | receptor-directed | 2 |
| 281 | replication-born | 3 |
| 282 | reproductive-related | 5 |
| 283 | rifampicin/minocycline-impregnated | 7 |
| 284 | ronkoleykin | 1 |
| 285 | rrna-derived | 1 |
| 286 | rs10993994 | 3 |
| 287 | rsmz | 1 |
| 288 | scratch-like | 2 |
| 289 | screening-instruments | 1 |
| 290 | self-life | 1 |
| 291 | self-propagating | 4 |
| 292 | sensititre | 8 |
| 293 | sensory/nociceptor | 1 |
| 294 | sequus | 2 |
| 295 | sheepish | 1 |
| 296 | shorter-lasting | 2 |
| 297 | sigtuna | 1 |
| 298 | simulated-aged | 1 |
| 299 | single-action | 2 |
| 300 | single-cycle | 6 |
| 301 | single-indicator | 4 |
| 302 | single-rod | 9 |
| 303 | single-sourced | 5 |
| 304 | sirt1-related | 1 |
| 305 | size-1 | 2 |
| 306 | size-fractioned | 1 |
| 307 | so-called | 769 |
| 308 | soil-associated | 2 |
| 309 | soil-bound | 1 |
| 310 | src-3+/ar-/syp+ | 2 |
| 311 | stealth | 6 |
| 312 | steroidal | 249 |
| 313 | strip-test | 1 |
| 314 | structurally-related | 4 |
| 315 | superimposes | 1 |
| 316 | sur2a | 6 |
| 317 | surface-adsorbed | 2 |
| 318 | surface-modifying | 1 |
| 319 | surface-protected | 1 |
| 320 | switched-to | 1 |
| 321 | symplicity | 47 |
| 322 | t-helper-2-type | 1 |
| 323 | tamper-resistant | 5 |
| 324 | tarsocrural | 4 |
| 325 | tcm-derived | 7 |
| 326 | tcm. | 1 |
| 327 | tcr-specific | 1 |
| 328 | three-miktoarm | 1 |
| 329 | thrombocyte-rich | 1 |
| 330 | thymus-implanted | 1 |
| 331 | tlr3-activated | 2 |
| 332 | top-prescribed | 1 |
| 333 | transporter-based | 1 |
| 334 | transsylvian | 1 |
| 335 | triphasic | 144 |
| 336 | triple-chamber | 3 |
| 337 | tyrosine-reduced | 1 |
| 338 | vaginally-acquired | 1 |
| 339 | vaidya | 5 |
| 340 | valsartan-based | 10 |
| 341 | value-ordered | 2 |
| 342 | vapor-a | 1 |
| 343 | very-high | 13 |
| 344 | water-related | 8 |
| 345 | wax-intercalated | 1 |
| 346 | well-being-includes | 1 |
| 347 | well-populated | 1 |
| 348 | wide-brimmed | 2 |
| 349 | wingless-type | 4 |
| 350 | workplace-related | 4 |
| 351 | wrong-way | 3 |
| 352 | xanthophyll-cycle | 2 |
| 353 | xiebai | 2 |
| 354 | zhenju | 2 |
| 355 | zno-1 | 3 |
| 356 | zno-2 | 2 |
| 357 | α-class | 2 |
| 358 | α4β2*-type | 1 |
| 359 | ∼100,000 | 1 |
| 1 | lag-3+ | 2 |
| 2 | cd83+ | 1 |
| 3 | osteocalcin+ | 1 |
| 4 | src-3+/ar-/syp+ | 2 |
| 5 | cd45-/cd144+/kdr+ | 1 |
| 6 | oth- | 1 |
| 7 | non-self. | 1 |
| 8 | tcm. | 1 |
| 9 | arb/ccb/ | 1 |
| 10 | aceis/ | 1 |
| 11 | ∼100,000 | 1 |
| 12 | lng-20 | 34 |
| 13 | 19370 | 1 |
| 14 | size-1 | 2 |
| 15 | zno-1 | 3 |
| 16 | non-glp-1 | 2 |
| 17 | zno-2 | 2 |
| 18 | anti-cox-2 | 3 |
| 19 | 1.2.3.2 | 1 |
| 20 | 71,112 | 1 |
| 21 | 3192 | 2 |
| 22 | f-cuins2 | 3 |
| 23 | passaged-3 | 1 |
| 24 | 1.2.4 | 3 |
| 25 | 43,082.5-43,142.4 | 1 |
| 26 | 21,914.5-21,974.4 | 1 |
| 27 | 19,942.9-21,974.4 | 1 |
| 28 | hcrnav34 | 4 |
| 29 | 23,764 | 1 |
| 30 | 3,294 | 4 |
| 31 | rs10993994 | 3 |
| 32 | 1.2.5 | 3 |
| 33 | 22-12-2005 | 1 |
| 34 | alpha5 | 4 |
| 35 | mir-103/7 | 1 |
| 36 | gbz188-2007 | 1 |
| 37 | 5,438 | 1 |
| 38 | 39049 | 1 |
| 39 | vapor-a | 1 |
| 40 | sur2a | 6 |
| 41 | fe₃o₄-plla-peg-plla | 2 |
| 42 | sigtuna | 1 |
| 43 | alimenta | 1 |
| 44 | vaidya | 5 |
| 45 | b-zr-b | 1 |
| 46 | hbsag-specific | 4 |
| 47 | gamma-gliadin-specific | 1 |
| 48 | fibrin-specific | 19 |
| 49 | tcr-specific | 1 |
| 50 | ingredient-specific | 1 |
| 51 | lmw-specific | 1 |
| 52 | non-biologic | 32 |
| 53 | nonbiologic | 16 |
| 54 | non-adrenergic | 7 |
| 55 | nonlipophilic | 2 |
| 56 | non-aurophilic | 2 |
| 57 | antiglycaemic | 1 |
| 58 | omic | 16 |
| 59 | non-estrogenic | 4 |
| 60 | prototypic | 44 |
| 61 | polycentric | 5 |
| 62 | triphasic | 144 |
| 63 | classic | 1,648 |
| 64 | non-diuretic | 4 |
| 65 | hypo-oncotic | 1 |
| 66 | nontherapeutic | 22 |
| 67 | non-sympatholytic | 1 |
| 68 | gastrotoxic | 2 |
| 69 | top-prescribed | 1 |
| 70 | most-prescribed | 3 |
| 71 | surface-adsorbed | 2 |
| 72 | single-sourced | 5 |
| 73 | tyrosine-reduced | 1 |
| 74 | laba/reduced | 1 |
| 75 | ifnb-induced | 1 |
| 76 | ncs-c-induced | 1 |
| 77 | cndac-induced | 1 |
| 78 | assist-as-needed | 6 |
| 79 | one-handed | 11 |
| 80 | nonbranded | 9 |
| 81 | pharmacist-recorded | 1 |
| 82 | melt-extruded | 2 |
| 83 | simulated-aged | 1 |
| 84 | cardio-enriched | 4 |
| 85 | nucleobase-modified | 1 |
| 86 | cisplatin-modified | 1 |
| 87 | cox-2‑modified | 1 |
| 88 | parent-identified | 3 |
| 89 | nitroxide-labeled | 1 |
| 90 | so-called | 769 |
| 91 | wide-brimmed | 2 |
| 92 | otj-trained | 1 |
| 93 | hads-defined | 1 |
| 94 | size-fractioned | 1 |
| 95 | hypoxia-preconditioned | 2 |
| 96 | looped | 14 |
| 97 | citrate-capped | 1 |
| 98 | value-ordered | 2 |
| 99 | prestorage-filtered | 2 |
| 100 | vaginally-acquired | 1 |
| 101 | intrinsic/acquired | 1 |
| 102 | hrp2-based | 1 |
| 103 | amyloid-based | 3 |
| 104 | nanostructure-based | 3 |
| 105 | lactose-based | 4 |
| 106 | non-lactose-based | 1 |
| 107 | belief-based | 10 |
| 108 | hrpii-based | 2 |
| 109 | 1-ethyl-3-methylimidazolium-based | 1 |
| 110 | valsartan-based | 10 |
| 111 | transporter-based | 1 |
| 112 | adenovirus-based | 4 |
| 113 | heat-released | 4 |
| 114 | intracellular-localised | 1 |
| 115 | community-diagnosed | 1 |
| 116 | commonly-used | 33 |
| 117 | etoricoxib-treated | 1 |
| 118 | pei-β-cyd-treated | 1 |
| 119 | ftnl-treated | 1 |
| 120 | dasatinib-pretreated | 1 |
| 121 | arb-pretreated | 1 |
| 122 | et-conjugated | 1 |
| 123 | microbial-associated | 5 |
| 124 | soil-associated | 2 |
| 125 | isotretinoin-associated | 1 |
| 126 | heterochromatin-associated | 1 |
| 127 | meso-erythritol-intercalated | 1 |
| 128 | wax-intercalated | 1 |
| 129 | sirt1-related | 1 |
| 130 | bzd-related | 1 |
| 131 | workplace-related | 4 |
| 132 | reproductive-related | 5 |
| 133 | incretin-related | 3 |
| 134 | water-related | 8 |
| 135 | structurally-related | 4 |
| 136 | animacy-violated | 5 |
| 137 | pi3kγ-regulated | 1 |
| 138 | nonregulated | 2 |
| 139 | nt-3-stimulated | 1 |
| 140 | well-populated | 1 |
| 141 | dearabinosylated | 1 |
| 142 | ixygenated | 1 |
| 143 | rifampicin/minocycline-impregnated | 7 |
| 144 | non-rifampicin-impregnated | 2 |
| 145 | heparin-impregnated | 1 |
| 146 | more-chlorinated | 1 |
| 147 | high-chlorinated | 2 |
| 148 | non-fluorinated | 5 |
| 149 | hypusinated | 1 |
| 150 | citrate-coated | 3 |
| 151 | eim-generated | 1 |
| 152 | lag-3-activated | 1 |
| 153 | tlr3-activated | 2 |
| 154 | cox-2‑transfected | 2 |
| 155 | cellular-connected | 1 |
| 156 | receptor-directed | 2 |
| 157 | injury-group-detected | 1 |
| 158 | surface-protected | 1 |
| 159 | non-targeted | 50 |
| 160 | ngr-targeted | 1 |
| 161 | thymus-implanted | 1 |
| 162 | behavior-oriented | 1 |
| 163 | pl-supplemented | 4 |
| 164 | il-2-boosted | 1 |
| 165 | rrna-derived | 1 |
| 166 | hucb-derived | 1 |
| 167 | tcm-derived | 7 |
| 168 | imidazolium-derived | 1 |
| 169 | non-fda-approved | 3 |
| 170 | igeκ-sensitized | 1 |
| 171 | glucose-and | 1 |
| 172 | high-and | 3 |
| 173 | soil-bound | 1 |
| 174 | myofibril-bound | 1 |
| 175 | gnp-bound | 3 |
| 176 | biochar-bound | 1 |
| 177 | single-rod | 9 |
| 178 | nonstandard | 34 |
| 179 | dsg/gsd | 1 |
| 180 | non-thiazide | 4 |
| 181 | lng+ee | 2 |
| 182 | dsg+ee | 3 |
| 183 | dehp-free | 5 |
| 184 | contrast-free | 2 |
| 185 | self-life | 1 |
| 186 | levodopa-the | 1 |
| 187 | emotions-the | 1 |
| 188 | benzodiazepine-like | 5 |
| 189 | scratch-like | 2 |
| 190 | first-available | 1 |
| 191 | currently-available | 5 |
| 192 | low-to-negligible | 1 |
| 193 | quasireversible | 3 |
| 194 | single-cycle | 6 |
| 195 | xanthophyll-cycle | 2 |
| 196 | 2,3-diaryl-indole | 8 |
| 197 | help-me | 2 |
| 198 | first‑line | 2 |
| 199 | nonclozapine | 1 |
| 200 | nitrotirosine | 1 |
| 201 | non-paroxetine | 4 |
| 202 | non-fluoxetine | 1 |
| 203 | α4β2*-type | 1 |
| 204 | t-helper-2-type | 1 |
| 205 | coated-type | 1 |
| 206 | pgsi-type | 1 |
| 207 | wingless-type | 4 |
| 208 | sensititre | 8 |
| 209 | lowest-dose | 4 |
| 210 | lowdose | 2 |
| 211 | pre-close | 3 |
| 212 | hyperdiverse | 1 |
| 213 | morse | 18 |
| 214 | adaptive-use | 2 |
| 215 | nonsalicylate | 1 |
| 216 | non-hydroxamate | 1 |
| 217 | good-moderate | 1 |
| 218 | antihypertenive | 1 |
| 219 | radio-responsive | 1 |
| 220 | nonulcerative | 29 |
| 221 | non-cox-2-selective | 3 |
| 222 | atrial-selective | 10 |
| 223 | cardio-selective | 6 |
| 224 | non-cox-selective | 1 |
| 225 | emotion-sensitive | 3 |
| 226 | large-size | 17 |
| 227 | antiresorbing | 1 |
| 228 | enzyme-inducing | 34 |
| 229 | non-enzyme-inducing | 6 |
| 230 | hsp60-binding | 1 |
| 231 | cyp2d6-blocking | 1 |
| 232 | glua2-containing | 2 |
| 233 | 3hdd-containing | 1 |
| 234 | glycine-containing | 2 |
| 235 | chemokine-containing | 2 |
| 236 | non-drospirenone-containing | 1 |
| 237 | levonorgestrel-containing | 10 |
| 238 | cadmium-containing | 1 |
| 239 | 4-ring | 4 |
| 240 | potassium-sparing | 53 |
| 241 | microtubule-interfering | 1 |
| 242 | alexandrium-causing | 1 |
| 243 | self-propagating | 4 |
| 244 | nonvasodilating | 9 |
| 245 | methylating | 11 |
| 246 | qi-invigorating | 5 |
| 247 | ppar-gamma-activating | 1 |
| 248 | non-ppargamma-activating | 1 |
| 249 | pfhrp2-detecting | 1 |
| 250 | competing | 910 |
| 251 | power-limiting | 1 |
| 252 | shorter-lasting | 2 |
| 253 | surface-modifying | 1 |
| 254 | desynchronizing | 2 |
| 255 | anti-illicit-drug | 3 |
| 256 | thrombocyte-rich | 1 |
| 257 | very-high | 13 |
| 258 | sheepish | 1 |
| 259 | half-strength | 11 |
| 260 | stealth | 6 |
| 261 | xiebai | 2 |
| 262 | irs-ii | 1 |
| 263 | mid-risk | 3 |
| 264 | classical | 1,951 |
| 265 | steroidal | 249 |
| 266 | cox2-preferential | 1 |
| 267 | maculo-canal | 1 |
| 268 | daily/occasional | 1 |
| 269 | non-traditional | 128 |
| 270 | nontraditional | 132 |
| 271 | nonconventional | 26 |
| 272 | non-hormonal | 90 |
| 273 | tarsocrural | 4 |
| 274 | no-tunnel | 1 |
| 275 | muassel | 1 |
| 276 | prozessmodell | 1 |
| 277 | core/shell/shell | 3 |
| 278 | non-3'-sl | 1 |
| 279 | 4.0-cm | 3 |
| 280 | 46-item | 3 |
| 281 | 5-nm | 1 |
| 282 | low-symptom | 1 |
| 283 | three-miktoarm | 1 |
| 284 | ch'an | 2 |
| 285 | corinthian | 2 |
| 286 | transsylvian | 1 |
| 287 | life-when | 1 |
| 288 | denv-3-driven | 1 |
| 289 | cone-driven | 1 |
| 290 | non-naproxen | 12 |
| 291 | nonnaproxen | 3 |
| 292 | pbca-allicin | 3 |
| 293 | phytoplankton-origin | 1 |
| 294 | ronkoleykin | 1 |
| 295 | non-aspirin | 23 |
| 296 | -statin | 1 |
| 297 | liqudation | 2 |
| 298 | non-third-generation | 1 |
| 299 | older-generation | 8 |
| 300 | current-generation | 4 |
| 301 | single-action | 2 |
| 302 | non-dissection | 2 |
| 303 | replication-born | 3 |
| 304 | head-worn | 3 |
| 305 | homegrown | 2 |
| 306 | di-ortho | 1 |
| 307 | crt-no | 1 |
| 308 | clopidogrel/no | 1 |
| 309 | nupro | 4 |
| 310 | progastro | 1 |
| 311 | switched-to | 1 |
| 312 | lab-on-a-chip | 7 |
| 313 | 0-84-year | 1 |
| 314 | triple-chamber | 3 |
| 315 | anti-her | 6 |
| 316 | newer | 2,353 |
| 317 | single-indicator | 4 |
| 318 | sensory/nociceptor | 1 |
| 319 | omics | 73 |
| 320 | clinopodioides | 2 |
| 321 | well-being-includes | 1 |
| 322 | 2-series | 4 |
| 323 | superimposes | 1 |
| 324 | non-cannabis | 2 |
| 325 | onsolis | 1 |
| 326 | necessity-concerns | 5 |
| 327 | cdse-zns | 1 |
| 328 | cdse/zns | 6 |
| 329 | odontológicos | 1 |
| 330 | iatrikos | 1 |
| 331 | α-class | 2 |
| 332 | screening-instruments | 1 |
| 333 | non-orthologous | 1 |
| 334 | sequus | 2 |
| 335 | double-hit | 4 |
| 336 | desault | 1 |
| 337 | enzyme-resistant | 1 |
| 338 | tamper-resistant | 5 |
| 339 | all-swcnt | 2 |
| 340 | full-time-equivalent | 1 |
| 341 | off-patent | 8 |
| 342 | polypotent | 1 |
| 343 | strip-test | 1 |
| 344 | 'first | 17 |
| 345 | zhenju | 2 |
| 346 | cd3+cd4+cd25+cd127low | 1 |
| 347 | lower-glycemic-index | 1 |
| 348 | fourteen-day | 10 |
| 349 | wrong-way | 3 |
| 350 | ido1-deficiency | 1 |
| 351 | mdr-family | 1 |
| 352 | non-thoracotomy | 5 |
| 353 | nonthoracotomy | 7 |
| 354 | circumplanetary | 1 |
| 355 | nonhereditary | 3 |
| 356 | symplicity | 47 |
| 357 | low-volume/low-intensity | 1 |
| 358 | rsmz | 1 |
| 359 | pandb-al₂o₃ | 1 |